UK-based Ockham Biotech has announced that data from a Phase 2b study of its inhaled heparin for the treatment of COPD demonstrate significant improvement in lung function compared to placebo, with improvements maintained for 7 days after cessation of treatment and no adverse events.
The study involved 24 moderate-to-severe COPD patients who received either nebulized heparin or a placebo over 21 days. Significant improvements were seen in FEV1, forced vital capacity, inspiratory capacity, total lung capacity, and residual volume, plus distance covered in a 6-minute walking test.
Ockham Scientific Director Janis Shute commented, “We are really excited by the significant findings from the study which builds on the extensive preclinical work we have undertaken with unfractionated heparin. There is the distinct potential for modification of the COPD disease process and getting closer to the goal of alleviating symptoms in these difficult to treat patients.”
The company is also developing inhaled heparin for the treatment of cystic fibrosis.
